ESSA Pharma - EPIX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $20.00
  • Forecasted Upside: 502.41 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.32
▼ -0.15 (-4.32%)

This chart shows the closing price for EPIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ESSA Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPIX

Analyst Price Target is $20.00
▲ +502.41% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for ESSA Pharma in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 502.41% upside from the last price of $3.32.

This chart shows the closing price for EPIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in ESSA Pharma. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2022Piper SandlerLower Target$50.00 ➝ $20.00High
8/16/2021OppenheimerLower TargetOutperform$36.00 ➝ $22.00Medium
3/4/2021Piper SandlerInitiated CoverageOverweight$50.00Medium
2/25/2021HC WainwrightLower TargetBuy$36.00 ➝ $32.00Low
2/12/2021Bloom BurtonReiterated RatingBuyN/A
2/11/2021OppenheimerBoost TargetOutperform$20.00 ➝ $36.00Low
2/11/2021HC WainwrightBoost TargetBuy$17.00 ➝ $36.00Low
1/14/2021OppenheimerBoost TargetOutperform$9.00 ➝ $20.00Low
1/11/2021HC WainwrightBoost TargetBuy$10.00 ➝ $17.00High
11/2/2020Jefferies Financial GroupInitiated CoverageBuy$17.00High
8/10/2020OppenheimerReiterated RatingBuy$9.00Medium
7/15/2020OppenheimerInitiated CoverageBuy$9.00Medium
6/22/2020OppenheimerReiterated RatingBuy$8.00High
5/24/2020Bloom BurtonReiterated RatingBuy$9.00High
5/15/2020HC WainwrightReiterated RatingBuyMedium
5/8/2020OppenheimerReiterated RatingBuy$8.00Low
10/24/2019OppenheimerInitiated CoverageOutperform$8.00Low
5/17/2019HC WainwrightReiterated RatingBuyHigh
2/15/2019HC WainwrightReiterated RatingBuyLow
3/26/2018HC WainwrightInitiated CoverageBuy$0.70Medium
1/18/2018Bloom BurtonUpgradeHold ➝ BuyHigh
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/11/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/10/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/10/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/8/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/7/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

ESSA Pharma logo
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $3.32
Low: $3.23
High: $3.44

50 Day Range

MA: $2.81
Low: $1.50
High: $4.82

52 Week Range

Now: $3.32
Low: $1.40
High: $14.88

Volume

91,586 shs

Average Volume

1,118,670 shs

Market Capitalization

$146.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04

Frequently Asked Questions

What sell-side analysts currently cover shares of ESSA Pharma?

The following equities research analysts have issued reports on ESSA Pharma in the last year: Piper Sandler.
View the latest analyst ratings for EPIX.

What is the current price target for ESSA Pharma?

1 Wall Street analysts have set twelve-month price targets for ESSA Pharma in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 502.4%. Piper Sandler has the highest price target set, predicting EPIX will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $20.00 for ESSA Pharma in the next year.
View the latest price targets for EPIX.

What is the current consensus analyst rating for ESSA Pharma?

ESSA Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EPIX.

What other companies compete with ESSA Pharma?

How do I contact ESSA Pharma's investor relations team?

ESSA Pharma's physical mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company's listed phone number is 778-331-0962 and its investor relations email address is [email protected] The official website for ESSA Pharma is www.essapharma.com. Learn More about contacing ESSA Pharma investor relations.